Coronary Atherosclerosis in Athletes: Exploring the Role of Sporting Discipline

Note: Funding Information: Please note: This work was supported by a grant from SPORTCOR, a Dutch national registry of sudden cardiac arrest in athletes, the Foundations “Wetenschappelijk Onderzoek Hart-en Vaatziekten” and “Bijstand Meander Medical Center” Amersfoort, the Röntgen Foundation Utrecht and Philips Healthcare. Drs. Aengevaeren and Eijsvogels are financially supported by grants from the Dutch Heart Foundation (#2017T088 and #2017T051, respectively). Dr. Thompson has received grant support from Sanofi, Regeneron, Esperion, Amarin, and Amgen; has served as a consultant for Amgen, Regeneron, Sanofi, and Esperion; has received speaker honoraria from Amarin, Sanofi, Regeneron, Amgen, and Kowa; and owns stock in Abbvie, Abbott Labs, CVS, General Electric, Johnson & Johnson, Medtronic, Sarepta, Boston Scientific, and Myokardia. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: This work was supported by a grant from SPORTCOR, a Dutch national registry of sudden cardiac arrest in athletes, the Foundations “Wetenschappelijk Onderzoek Hart-en Vaatziekten” and “Bijstand Meander Medical Center” Amersfoort, the Röntgen Foundation Utrecht and Philips Healthcare. Drs. Aengevaeren and Eijsvogels are financially supported by grants from the Dutch Heart Foundation (#2017T088 and #2017T051, respectively). Dr. Thompson has received grant support from Sanofi, Regeneron, Esperion, Amarin, and Amgen; has served as a consultant for Amgen, Regeneron, Sanofi, and Esperion; has received speaker honoraria from Amarin, Sanofi, Regeneron, Amgen, and Kowa; and owns stock in Abbvie, Abbott Labs, CVS, General Electric, Johnson & Johnson, Medtronic, Sarepta, Boston Scientific, and Myokardia. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.